Englishhe present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system.; In a further preferred aspect, the invention relates to the use of the polymer conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis. In a still further aspect, the invention relates to the use of the polymer conjugates in the prevention, alleviation and treatment of NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula.
| Data di concessione: | 2007 |
| Titolo: | POLYMER CONJUGATES OF K-252A AND DERIVATIVES THEREOF |
| Inventore del brevetto: | S. Traversa; R. Bagnod; D. Barone L. Beratarione Rava Rossa; S. Fumero; V. Mainero; A. Marconi; C. Oderda; C. Pincelli; C. Lorenzetto; L. Beccaria |
| Autori: | |
| Abstract: | he present invention relates to novel polymer conjugates of K-252a and derivatives thereof and to their use for the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of kinase-associated pathologies. In particular, the present invention relates to the prevention, alleviation and treatment of HMGB1-associated pathologies. In a particular aspect, the invention relates to the use of the novel polymer conjugates of K-252a and derivatives thereof in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of neurological disorders, neuropathies and neurodegenerative disorders of the central and peripheral nervous system.; In a further preferred aspect, the invention relates to the use of the polymer conjugates in the preparation of a pharmaceutical composition useful for the prevention, alleviation and treatment of dermal pathologies, in particular dermal pathologies associated with an excessive keratinocyte proliferation, in particular psoriasis. In a still further aspect, the invention relates to the use of the polymer conjugates in the prevention, alleviation and treatment of NGF-related pain. More specifically, the present invention relates to a polymer conjugate of K-252a and derivatives thereof, wherein the polymer is polyethylene glycol or methoxy-polyethylene glycol formula. |
| Handle: | http://hdl.handle.net/11380/593346 |
| Titolare del brevetto: | CREABILIS THERAPEUTICS S P A [IT]; TRAVERSA SILVIO [IT]; BAGNOD RAFFAELLA [IT]; BARONE DOMENICO [IT]; BERTARIONE RAVA ROSSA LUISA [IT]; FUMERO SILVANO [IT]; MAINERO VALENTINA [IT]; MARCONI ALESSANDRA [IT]; ODERDA CECILIA [CH]; PINCELLI CARLO [IT]; LORENZETTO CHIARA [IT]; BECCARIA LUCA [IT] |
| Numero di deposito: | WO2007022999 |
| Appare nelle tipologie: | Brevetto |
File in questo prodotto:
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
Copyright © 2018